

KEWAUNEE SCIENTIFIC CORP /DE/

Form 10-Q

September 12, 2008

Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 10-Q**

**x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended July 31, 2008 or

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-5286

**KEWAUNEE SCIENTIFIC CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**38-0715562**  
(IRS Employer  
Identification No.)

**2700 West Front Street**

**Statesville, North Carolina**  
(Address of principal executive offices)

**28677-2927**  
(Zip Code)

**Registrant's telephone number, including area code: (704) 873-7202**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No

As of September 5, 2008, the registrant had outstanding 2,556,202 shares of Common Stock.

**Table of Contents**

**KEWAUNEE SCIENTIFIC CORPORATION**

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JULY 31, 2008

|  | <b>Page Number</b> |
|--|--------------------|
| <b>PART I. <u>FINANCIAL INFORMATION</u></b>  |                    |
| Item 1. <u>Financial Statements</u>  |                    |
| <u>Consolidated Statements of Operations - Three months ended July 31, 2008 and 2007</u>             | 3                  |
| <u>Consolidated Balance Sheets July 31, 2008 and April 30, 2008</u>                                  | 4                  |
| <u>Consolidated Statements of Cash Flows - Three months ended July 31, 2008 and 2007</u>             | 5                  |
| <u>Notes to Consolidated Financial Statements</u>  | 6                  |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 9                  |
| <u>Review by Independent Registered Public Accounting Firm</u>                                       | 13                 |
| <u>Report of Independent Registered Public Accounting Firm</u>                                       | 14                 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>                            | 15                 |
| Item 4. <u>Controls and Procedures</u>   | 15                 |
| <b>PART II. <u>OTHER INFORMATION</u></b>   |                    |
| Item 4. <u>Submission of Matters to a Vote of Security Holders</u>                                   | 16                 |
| Item 6. <u>Exhibits</u>  | 16                 |
| <u>SIGNATURE</u>   | 17                 |

**Table of Contents**

## Part 1. Financial Information

## Item 1. Financial Statements

*Kewaunee Scientific Corporation*

## Consolidated Statements of Operations

*(Unaudited)**(in thousands, except per share data)*

|   | <b>Three months ended</b> |             |
|---|---------------------------|-------------|
|   | <b>July 31</b>            |             |
|   | <b>2008</b>               | <b>2007</b> |
| Net sales   | \$ 25,395                 | \$ 20,784   |
| Costs of products sold  | 20,044                    | 16,521      |
| Gross profit  | 5,351                     | 4,263       |
| Operating expenses  | 3,586                     | 3,148       |
| Operating earnings  | 1,765                     | 1,115       |
| Other income (expense)  | (38)                      | 3           |
| Interest expense  | (89)                      | (110)       |
| Earnings before income taxes  | 1,638                     | 1,008       |
| Income tax expense  | 541                       | 312         |
| Earnings before minority interests                                  | 1,097                     | 696         |
| Minority interests in subsidiaries                                  | 116                       | 22          |
| Net earnings  | \$ 981                    | \$ 674      |
| Net earnings per share  |                           |             |
| Basic   | \$ 0.38                   | \$ 0.27     |
| Diluted   | \$ 0.38                   | \$ 0.27     |
| Weighted average number of common shares outstanding (in thousands) |                           |             |
| Basic   | 2,551                     | 2,502       |
| Diluted   | 2,570                     | 2,521       |

*See accompanying notes to consolidated financial statements.*

**Table of Contents***Kewaunee Scientific Corporation*

## Consolidated Balance Sheets

*(in thousands)*

|  | July 31,<br>2008<br>(Unaudited) | April 30,<br>2008 |
|--|---------------------------------|-------------------|
| <b><u>Assets</u></b>                               |                                 |                   |
| Current assets:                                    |                                 |                   |
| Cash and cash equivalents                          | \$ 3,131                        | \$ 3,784          |
| Restricted cash                                    | 439                             | 480               |
| Receivables, less allowance                        | 22,969                          | 20,087            |
| Inventories  | 7,310                           | 6,984             |
| Deferred income taxes                              | 405                             | 407               |
| Prepaid expenses and other current assets          | 841                             | 1,440             |
| <b>Total current assets</b>                        | <b>35,095</b>                   | <b>33,182</b>     |
| Property, plant and equipment, at cost             | 39,957                          | 39,186            |
| Accumulated depreciation                           | (27,915)                        | (27,361)          |
| <b>Net property, plant and equipment</b>           | <b>12,042</b>                   | <b>11,825</b>     |
| Prepaid pension cost                               | 1,996                           | 1,936             |
| Other  | 3,577                           | 3,663             |
| <b>Total other assets</b>                          | <b>5,573</b>                    | <b>5,599</b>      |
| <b>Total Assets</b>                                | <b>\$ 52,710</b>                | <b>\$ 50,606</b>  |
| <b><u>Liabilities and Stockholders' Equity</u></b> |                                 |                   |
| Current liabilities:                               |                                 |                   |
| Short-term borrowings                              | \$ 5,707                        | \$ 4,551          |
| Current obligations under capital leases           | 291                             | 323               |
| Accounts payable                                   | 8,928                           | 8,929             |
| Employee compensation and amounts withheld         | 1,444                           | 2,026             |
| Deferred revenue                                   | 695                             | 667               |
| Other accrued expenses                             | 1,706                           | 766               |
| <b>Total current liabilities</b>                   | <b>18,771</b>                   | <b>17,262</b>     |
| Obligations under capital leases                   | 90                              | 153               |
| Deferred income tax                                | 921                             | 921               |
| Accrued employee benefit plan costs                | 3,488                           | 3,555             |
| Minority interests in subsidiaries                 | 1,847                           | 1,768             |
| <b>Total Liabilities</b>                           | <b>25,117</b>                   | <b>23,659</b>     |
| Stockholders' equity:                              |                                 |                   |
| Common stock                                       | 6,550                           | 6,550             |
| Additional paid-in-capital                         | 492                             | 489               |
| Retained earnings                                  | 23,149                          | 22,373            |
| Accumulated other comprehensive loss               | (2,177)                         | (2,041)           |
| Common stock in treasury, at cost                  | (421)                           | (424)             |
| <b>Total stockholders' equity</b>                  | <b>27,593</b>                   | <b>26,947</b>     |

Edgar Filing: KEWAUNEE SCIENTIFIC CORP /DE/ - Form 10-Q

|  |           |           |
|--|-----------|-----------|
| Total Liabilities and Stockholders' Equity | \$ 52,710 | \$ 50,606 |
|--|-----------|-----------|

*See accompanying notes to consolidated financial statements.*

**Table of Contents***Kewaunee Scientific Corporation*

## Consolidated Statements of Cash Flows

*(Unaudited)**(in thousands )*

|   | <b>Three months ended<br/>July 31</b> |                 |
|---|---------------------------------------|-----------------|
|   | <b>2008</b>                           | <b>2007</b>     |
| <b><i>Cash flows from operating activities:</i></b>                             |                                       |                 |
| Net earnings  | \$ 981                                | \$ 674          |
| Adjustments to reconcile net earnings to net cash used in operating activities: |                                       |                 |
| Depreciation  | 568                                   | 494             |
| Bad debt provision  | 33                                    | 88              |
| Provision for deferred income tax expense                                       | 2                                     |                 |
| Decrease in prepaid income taxes  | 812                                   |                 |
| (Increase) decrease in receivables  | (2,915)                               | 105             |
| (Increase) decrease in inventories  | (326)                                 | 175             |
| Increase in prepaid pension cost  | (60)                                  | (114)           |
| Increase (decrease) in accounts payable and other accrued expenses              | 357                                   | (1,133)         |
| Increase (decrease) in deferred revenue   | 28                                    | (960)           |
| Other, net  | (206)                                 | (342)           |
| Net cash used in operating activities   | (726)                                 | (1,013)         |
| <b><i>Cash flows from investing activities:</i></b>                             |                                       |                 |
| Capital expenditures  | (785)                                 | (435)           |
| Decrease (increase) in restricted cash  | 41                                    | (24)            |
| Net cash used in investing activities   | (744)                                 | (459)           |
| <b><i>Cash flows from financing activities:</i></b>                             |                                       |                 |
| Dividends paid  | (205)                                 | (175)           |
| Increase in short-term borrowings   | 1,156                                 | 1,067           |
| Payments on capital leases  | (95)                                  | (86)            |
| Proceeds from exercise of stock options (including tax benefit)                 | 6                                     | 190             |
| Net cash provided by financing activities                                       | 862                                   | 996             |
| Effect of exchange rate changes on cash   | (45)                                  | 36              |
| <b><i>Decrease in cash and cash equivalents</i></b>                             | <b>(653)</b>                          | <b>(440)</b>    |
| <b><i>Cash and cash equivalents, beginning of period</i></b>                    | <b>3,784</b>                          | <b>2,231</b>    |
| <b><i>Cash and cash equivalents, end of period</i></b>                          | <b>\$ 3,131</b>                       | <b>\$ 1,791</b> |

See accompanying notes to consolidated financial statements.

**Table of Contents**

## Kewaunee Scientific Corporation

## Notes to Consolidated Financial Statements

(unaudited)

**A. Financial Information**

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the Company or Kewaunee) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the Commission). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's 2008 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

**B. Inventories**

Inventories consisted of the following (in thousands):

|                   | July 31, 2008 | April 30, 2008 |
|-------------------|---------------|----------------|
| Finished products | \$ 2,410      | \$ 1,920       |
| Work in process   | 1,261         | 1,099          |
| Raw materials     | 3,639         | 3,965          |
|                   | \$ 7,310      | \$ 6,984       |

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur.



**Table of Contents****C. Comprehensive Income**

A reconciliation of net earnings and total comprehensive income for the three months ended July 31, 2008 and 2007 is as follows (in thousands):

|   | Three months ended<br>July 31, 2008 | Three months ended<br>July 31, 2007 |
|---|-------------------------------------|-------------------------------------|
| Net earnings  | \$ 981                              | \$ 674                              |
| Change in cumulative foreign currency translation adjustments | (136)                               | 53                                  |
| <b>Total comprehensive income</b>                             | <b>\$ 845</b>                       | <b>\$ 727</b>                       |

Assets and liabilities for the Company's foreign subsidiaries are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders' equity.

**D. Segment Information**

The following table provides financial information by business segments for the three months ended July 31, 2008 and 2007 (in thousands):

|   | Domestic<br>Operations | International<br>Operations | Corporate | Total     |
|---|------------------------|-----------------------------|-----------|-----------|
| <b>Three months ended July 31, 2008</b>       |                        |                             |           |           |
| Revenues from external customers              | \$ 21,013              | \$ 4,382                    | \$        | \$ 25,395 |
| Intersegment revenues                         | 786                    | 4                           | (790)     |           |
| Operating earnings (loss) before income taxes | 2,040                  | 414                         | (816)     | 1,638     |
| <b>Three months ended July 31, 2007</b>       |                        |                             |           |           |
| Revenues from external customers              | \$ 18,014              | \$ 2,770                    | \$        | \$ 20,784 |
| Intersegment revenues                         | 776                    | 89                          | (865)     |           |
| Operating earnings (loss) before income taxes | 1,672                  | (2)                         | (662)     | 1,008     |

**E. Defined Pension Plans**

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. These plans were amended as of April 30, 2005, no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. No contributions were paid to the plans during the three months ended July 31, 2008, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year.

**Table of Contents**

Pension expense (income) consisted of the following (in thousands):

|                                    | <b>Three months ended<br/>July 31, 2008</b> | <b>Three months ended<br/>July 31, 2007</b> |
|------------------------------------|---|---|
| Service Cost                       | \$ -0-                                      | \$ -0-                                      |
| Interest Cost                      | 228   | 215   |
| Expected return on plan assets     | (337)                                       | (365)                                       |
| Recognition of net loss            | 49  | 35  |
| Net periodic pension cost (income) | \$ (60)                                     | \$ (115)                                    |

**Table of Contents**

Item 2. Management's Discussion and Analysis

of Financial Condition and Results of Operations

The Company's 2008 Annual Report to Stockholders contains management's discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2008. The following discussion and analysis describes material changes in the Company's financial condition since April 30, 2008. The analysis of results of operations compares the three months ended July 31, 2008 with the comparable period of the prior fiscal year.

**Results of Operations**

Sales for the three months ended July 31, 2008 were \$25,395,000, an increase of 22% from sales of \$20,784,000 in the same period last year. Sales from Domestic Operations were \$21,013,000, an increase of 17% from the prior year period. Sales from International Operations were \$4,382,000, an increase of 58% from the prior year period. The order backlog at July 31, 2008 was \$60.4 million, as compared to a backlog of \$58.7 million at April 30, 2008 and \$54.7 million at July 31, 2007.

The gross profit margin for the three months ended July 31, 2008 was 21.1% of sales, as compared to 20.5% of sales in the comparable quarter of the prior year. The increase in gross profit margin was due to increased manufacturing efficiencies, savings from alternative sources of raw materials and components, and other cost improvement initiatives, which more than offset higher prices paid during the quarter for certain raw materials, particularly steel and resin, and for energy and transportation.

Operating expenses for the three months ended July 31, 2008 were \$3.6 million, or 14.1% of sales, as compared to \$3.1 million, or 15.1% of sales, in the comparable period of the prior year. The decrease in operating expenses as a percentage of sales was due to most operating expenses staying relatively constant while sales increased. The increase in operating expenses in dollars was primarily due to increased expense recorded for performance incentive plans of \$182,000, increased administrative salaries expense of \$90,000, and increased sales and marketing expenses of \$76,000, partially offset by a decrease of \$59,000 in consulting expenses.

Operating earnings were \$1,765,000 for the three months ended July 31, 2008. This compares to operating earnings of \$1,115,000 for the comparable period of the prior year.

## Table of Contents

Interest expense was \$89,000 for the three months ended July 31, 2008, as compared to \$110,000 for the same period of the prior year. The decrease in interest expense for the current year period resulted from lower interest rates paid, partially offset by higher levels of borrowings, as compared to the prior year period.

The net of other income and other expense was an expense of \$38,000 in the three months ended July 31, 2008, as compared to income of \$3,000 for the comparable period of the prior year.

Income tax expense of \$541,000 was recorded for the three months ended July 31, 2008, as compared to income tax expense of \$312,000 recorded for the comparable period of the prior year. The effective tax rate was 33.0% for the three months ended July 31, 2008 and was 31.0% for the three months ended July 31, 2007. The effective tax rate for the three months ended July 31, 2008 differs from the statutory rate primarily due to the impact of varying income tax rates on income earned by the Company's foreign subsidiaries. In addition to this factor, the effective tax rate in the prior year period was favorably impacted by earned state and federal tax credits. The increase in the effective tax rate in the current year period as compared to the prior year period resulted primarily from the absence of tax credits no longer available because of the expiration of tax credits allowable to corporations under the United States Federal Research and Environmental Tax Credit Law.

Minority interests relate to minority shareholders' interest in the Company's two subsidiaries that are not 100% owned by the Company. Minority interests reduced net earnings by \$116,000 for the three months ended July 31, 2008, as compared to a reduction of \$22,000 for the comparable period of the prior year. The increase in minority interests in the current period was directly related to increased earnings of the two subsidiaries.

Net earnings were \$981,000, or \$0.38 per diluted share, for the three months ended July 31, 2008. This compares to net earnings of \$674,000, or \$0.27 per diluted share, for the comparable period of the prior year.

## Liquidity and Capital Resources

Historically, the Company's principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company's revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

## Table of Contents

The Company had working capital of \$16.3 million at July 31, 2008, compared to \$15.9 million at April 30, 2008. The ratio of current assets to current liabilities was 1.9-to-1 at July 31, 2008, unchanged from April 30, 2008. At July 31, 2008, advances of \$5,707,000 were outstanding under the unsecured credit facility, as compared to advances of \$4,551,000 outstanding as of April 30, 2008.

The Company's operations used cash of \$726,000 during the three months ended July 31, 2008. Cash was primarily used to fund an increase of \$2,915,000 in accounts receivable, which was partially offset by cash provided from operating earnings.

The Company's operations used cash of \$1,013,000 during the three months ended July 31, 2007. Cash was primarily used to fund a decrease in accounts payable and other accrued expenses as well as a decrease in deferred revenue. These items were partially offset by cash provided from operating earnings.

During the three months ended July 31, 2008, net cash of \$744,000 was used by investing activities, primarily for capital expenditures. This compares to the use of \$459,000 for investing activities in the same period of the prior year, primarily for capital expenditures.

The Company's financing activities provided cash of \$862,000 during the three months ended July 31, 2008. Cash provided included \$1,156,000 received from short-term borrowings which was partially offset by cash dividends paid of \$205,000 and payments on obligations of capital leases of \$95,000. Financing activities provided cash of \$996,000 in the same period of the prior year, which included \$1,067,000 received from short-term borrowings, partially offset by \$175,000 for cash dividends and \$86,000 for payments on obligations of capital leases.

## Outlook for Remainder of Fiscal Year 2009

While the Company's ability to predict future demand for its products continues to be limited given, among other general economic factors affecting the Company and its markets, the Company's role as subcontractor or supplier to dealers for subcontractors, the Company expects the remainder of fiscal year 2009 to be profitable. In addition to general economic factors affecting the Company and its markets, demand for its products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company's earnings are also impacted by increased costs of raw materials, including stainless steel, wood, and epoxy resin, and whether the Company is able to increase product prices to customers in amounts that correspond to such increases without materially and adversely affecting sales. Additionally, since prices are normally quoted on a firm basis in the industry, we bear the burden of possible increases in labor and material costs between the quotation of an order and delivery of a product.

**Table of Contents**

**Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995**

Certain statements in this report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the Reform Act ). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company s operations, markets, products, services, and prices, as well as prices for certain raw materials and energy. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms believes , belief , expects , plans , objectives , anticipates , intends or the like to be uncertain and forward-looking. Over time, the Company s results, performance or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by the Company s forward-looking statements, and such difference might be significant and harmful to stockholders interests. Many important factors that could cause such a difference are described under the caption Risk Factors, in Item 1A of the Company s 2008 Annual Report on Form 10-K.

**Table of Contents**

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim consolidated financial information included in this Quarterly Report on Form 10-Q for each of the three month periods ended July 31, 2008 and July 31, 2007 has been performed by Cherry, Bekaert & Holland, L.L.P., the Company's registered public accounting firm. Their report on the interim consolidated financial information follows.

**Table of Contents**

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have reviewed the accompanying consolidated balance sheets of Kewaunee Scientific Corporation and its subsidiaries (the Company) as of July 31, 2008, and the related consolidated statements of operations and of cash flows for the three-month periods ended July 31, 2008 and 2007. These interim consolidated financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the interim consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of April 30, 2008, and the related statements of operations, of stockholder's equity and of cash flows for the year then ended (not presented herein) and in our report dated July 12, 2008, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of April 30, 2008 is fairly stated in all material respects in relation to the consolidated financial statement from which it has been derived.

Cherry, Bekaert & Holland, L.L.P.

Charlotte, North Carolina

September 9, 2008



**Table of Contents**

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2008.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the Company's management, including the Chief Executive Officer ( CEO ) and Chief Financial Officer ( CFO ), of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of July 31, 2008. Based on that evaluation, the Company's management, including the CEO and CFO, concluded that, as of July 31, 2008, the Company's disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There was no significant change in the Company's internal control over financial reporting that occurred during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

## PART II. OTHER INFORMATION

## Item 4. Submission of Matters to a Vote of Security Holders

The Company's Annual Meeting of Stockholders was held on August 27, 2008. Each of the nominees for Class I directors was re-elected for a three-year term. The votes cast for and withheld from each such director were as follows:

| <b>Director</b>   | <b>For</b> | <b>Withheld</b> |
|-------------------|------------|-----------------|
| Wiley N. Caldwell | 1,985,744  | 373,236         |
| Silas Keehn       | 1,962,872  | 396,108         |
| David S. Rhind    | 2,046,523  | 312,457         |

The proposal to adopt the 2008 Key Employee Stock Option Plan was also approved. The votes cast for the Plan were as follows:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> |
|------------|----------------|----------------|
| 1,261,344  | 431,555        | 2,519          |

## Item 6. Exhibits and Reports on Form 8-K

- 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KEWAUNEE SCIENTIFIC CORPORATION  
(Registrant)

Date: September 12, 2008

By /s/ D. Michael Parker  
D. Michael Parker  
(As duly authorized officer and Senior Vice President, Finance and  
Chief Financial Officer)

17